D-0179-2021 Class II Terminated
FDA drug recall D-0179-2021 was initiated by Ascend Laboratories LLC on Dec 17, 2020 and is designated Class II. Reason for recall: Failed Impurity/Degradation Specifications The recall status is terminated (terminated May 3, 2023). Affected quantity: 9,524 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Jan 6, 2021
- Initiation Date
- Dec 17, 2020
- Termination Date
- May 3, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 9,524 bottles
Product description
Ascend Laboratories, llc Cephalexin for Oral Suspension, USP 250 mg per 5 mL 200 ml (when mixed) Rx Only Manufactured by: Alkem Laboratories, Ltd, Mumbai -400 013 INDIA Distributed by: Ascend Laboratories, LLC Parsippany, NJ 07054 NDC 67877-545-68
Reason for recall
Failed Impurity/Degradation Specifications
Distribution pattern
Nationwide
Code information
20141680, 20141681, 20141759
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0179-2021
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026